Heterodimeric IL-15 in Cancer Immunotherapy

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Immunotherapy is a key cancer treatment strategy.
• Interleukin-15 (IL-15) supports cytotoxic CD8+ T and natural killer (NK) cells, enhancing anti-tumor immunity.
• Bioactive IL-15 exists as heterodimeric IL-15 (hetIL-15), mimicking its natural form.

Purpose of the Study:

• To review the role and efficacy of IL-15-based immunotherapies in cancer treatment.
• To highlight the advantages of hetIL-15 and its variants over single-chain IL-15.
• To discuss the potential of IL-15 agents in converting immunologically 'cold' tumors to 'hot' tumors.

Main Methods:

• Review of preclinical animal studies on IL-15 agents.
• Analysis of clinical trial data for IL-15-based therapies.
• Comparison of pharmacokinetic and biological functions of different IL-15 agents.

Main Results:

• IL-15 agents, including hetIL-15 variants, demonstrate favorable pharmacokinetics and in vivo function compared to single-chain IL-15.
• Preclinical studies show IL-15 agents can promote tumor lymphocyte infiltration, converting "cold" tumors to "hot".
• Clinical trials indicate IL-15 therapies are well-tolerated, expanding and activating NK and CD8+ T cells.

Conclusions:

• IL-15-based therapies are effective in expanding and activating key anti-tumor immune cells.
• IL-15 agents represent a promising approach to enhance anti-tumor immunity and improve cancer treatment outcomes.
• Further investigation into combination therapies involving IL-15 agents is warranted to maximize clinical efficacy.